Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06360978 | Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer | not yet recruiting | Phase 2 | 30 | Assiut UniversityOTHER | 0 | Apr 11, 2024 | clinicaltrials |
| NCT06361030 | Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2024 |
| clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06354114 | A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 | not yet recruiting | Phase 2 | 80 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06354218 | Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06354530 | A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 / Phase 3 | 266 | Army Medical Center of PLAOTHER_GOV | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06355401 | Maintenance Hormonal Therapy and DLBCL | not yet recruiting | Phase 2 / Phase 3 | 100 | Sohag UniversityOTHER | 0 | Apr 9, 2024 | clinicaltrials |
| NCT05319249 | Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia(NAKIP-AML) | not yet recruiting | Phase 1 / Phase 2 | 54 | German Cancer Research CenterOTHER | 0 | Apr 5, 2024 | clinicaltrials |
| NCT06223711 | Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC | recruiting | Phase 2 | 43 | Universität des SaarlandesOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT06349967 | Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer | not yet recruiting | Phase 2 | 59 | West China HospitalOTHER | 0 | Apr 5, 2024 | clinicaltrials |
| NCT05984810 | NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101(FLUOPANC-II) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06250959 | RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.(BEAT-ALL-2024) | recruiting | Phase 2 | 124 | Chen SuningOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05477264 | Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type | recruiting | Phase 2 | 38 | Won Seog KimOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT05652920 | Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC | recruiting | Phase 1 / Phase 2 | 105 | OriCell Therapeutics Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06221748 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | recruiting | Phase 2 / Phase 3 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06345287 | Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC | recruiting | Phase 2 | 133 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06202001 | Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients | recruiting | Phase 1 / Phase 2 | 70 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341595 | Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM | recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341907 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | recruiting | Phase 2 / Phase 3 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04660760 | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 116 | Academic and Community Cancer Research UnitedOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05773079 | Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 28 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Apr 1, 2024 | clinicaltrials |
| NCT06339216 | A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer. | not yet recruiting | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 0 | Apr 1, 2024 | clinicaltrials |
| NCT05986071 | I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers(MATRIX) | not yet recruiting | Phase 1 / Phase 2 | 57 | Institut Paoli-CalmettesOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT06336954 | Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure | not yet recruiting | Phase 2 | 40 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Mar 29, 2024 | clinicaltrials |
| NCT06145074 | Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.(IMPULS) | recruiting | Phase 2 | 30 | Zealand University HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06335355 | A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | not yet recruiting | Phase 2 / Phase 3 | 401 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06332950 | Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy | not yet recruiting | Phase 1 / Phase 2 | 80 | Baohui HanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06333509 | Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL | not yet recruiting | Phase 1 / Phase 2 | 166 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 0 | Mar 27, 2024 | clinicaltrials |
| NCT05098119 | Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) | recruiting | Phase 2 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06331845 | Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06321289 | Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06327451 | Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma | recruiting | Phase 2 | 50 | Tianjin Medical University General HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06327698 | Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure | not yet recruiting | Phase 2 | 30 | Hunan Cancer HospitalOTHER | 0 | Mar 25, 2024 | clinicaltrials |
| NCT05861271 | Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer | recruiting | Phase 2 | 1,008 | Fudan UniversityOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06324994 | Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. | not yet recruiting | Phase 2 | 10 | Dalian Medical UniversityOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06196788 | Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer(PTCA199-9) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06319950 | High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases | not yet recruiting | Phase 2 | 255 | Taizhou HospitalOTHER | 0 | Mar 20, 2024 | clinicaltrials |
| NCT06227117 | Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer | recruiting | Phase 2 | 120 | RemeGen Co., Ltd.INDUSTRY | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05200988 | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC(Indi-Blade) | active not recruiting | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05280314 | Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors | recruiting | Phase 2 | 60 | IO BiotechINDUSTRY | 6 | Mar 18, 2024 | clinicaltrials |
| NCT06234007 | Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study | recruiting | Phase 2 | 45 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05425576 | OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition | not yet recruiting | Phase 2 | 63 | Oncotelic Inc.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06032052 | Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients | recruiting | Phase 2 | 49 | Hubei Cancer HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06232096 | A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. | recruiting | Phase 1 / Phase 2 | 154 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06259058 | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06304818 | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours. | not yet recruiting | Phase 1 / Phase 2 | 515 | Sinocelltech Ltd.INDUSTRY | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06310473 | Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial | not yet recruiting | Phase 2 | 30 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06304350 | Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 25 | Tongji UniversityOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT01686334 | Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission(WIDEA) | active not recruiting | Phase 2 | 130 | Zwi BernemanOTHER | 1 | Mar 12, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Apr 11, 2024source: clinicaltrials